The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid

Martin‐Moro, Fernando; Núñez-Torrón, Claudia; Pérez-Lamas, Lucía; Jiménez-Chillón, Carlos; Marquet-Palomanes, Juan; López-Jiménez, Francisco Javier; Herrera-Puente, Pilar

doi:10.1016/j.leukres.2021.106518

Cited by 6 publications

(4 citation statements)

References 13 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Martin-Moro et al [6] compared the clinical and laboratory presentations of the patients diagnosed with acute myeloid leukemia (AML) in the first three months of the pandemic and in the same months before the pandemic, in order to investigate the effects of a 3-month country-wide lockdown in Spain. They reported that the patients diagnosed during the pandemic admitted the hospital with worse performance status, higher bleeding rate, higher leukocyte count and lactate dehydrogenase (LDH) level, and lower hemoglobin level at the time of diagnosis.…”

Section: Introductionmentioning

confidence: 76%

“…They reported that the patients diagnosed during the pandemic admitted the hospital with worse performance status, higher bleeding rate, higher leukocyte count and lactate dehydrogenase (LDH) level, and lower hemoglobin level at the time of diagnosis. However, none of the variables reached a statistically significant difference between the groups [6] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic

Küçükyurt

Şahin²,

Yılmaz³

et al. 2022

Current Problems in Cancer

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 76%

Section: Introductionmentioning

confidence: 99%

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic

Küçükyurt

Şahin²,

Yılmaz³

et al. 2022

Current Problems in Cancer

View full text Add to dashboard Cite

“…Наиболее обсуждаемой проблемой с первых меся цев пандемии по настоящее время является тактика противоопухолевой терапии острых лейкозов как у па циентов с подтвержденной коронавирусной инфекци ей, так и у неинфицированных пациентов, находящих ся в группе риска заражения SARSCoV2. С одной стороны, острый лейкоз, как лимфобластный, так и миелобластный, требует начала специфической про тивоопухолевой терапии в кратчайшие сроки с момен та постановки диагноза и четкого соблюдения меж курсовых интервалов, так как считается, что задержка начала терапии и увеличение межкурсовых интервалов могут ухудшить результаты лечения, приводя к рискам резистентного течения и рецидива [31], а также повы шают риск смерти от осложнений лейкоза до начала противоопухолевой терапии [32]. С другой стороны, длительная нейтропения, вторичный иммунодефицит на фоне химиотерапевтического воздействия повыша ют риски развития вторичных инфекций, в том числе вирусных [20].…”

Section: противоопухолевая терапия у пациентов с острыми лейкозами в ...unclassified

COVID-19 in patients with acute leukemia: 3 years' experience of pandemic

Chudnova,

Misyurina,

Baryakh

et al. 2024

Onkogematologiâ

View full text Add to dashboard Cite

Patients with acute leukemia are one of the most vulnerable risk groups for infection with SARS-CoV-2 and severe course of coronavirus infection. During the first 2 years of the pandemic, the mortality rate of patients with acute leukemia was 11-48 %, depending on leukemia type, and only reached population levels in 2022. Risk factors for severe COVID-19 in patients with acute leukemia are old age, concomitant cardiac pathology, metabolic syndrome, and the absence of acute leukemia remission. Chemotherapy administered one month before hospitalization with COVID-19 diagnosis showed statistical significance in influencing hospital mortality only in the group of patients with acute myeloid leukemia. Despite this, the international medical community has recommended delaying the start of chemotherapy until clinical symptoms of coronavirus infection have completely resolved and a negative test result for SARS-CoV-2 has been obtained for all types of leukemia. Currently, the most optimal tactic is to prevent SARS-CoV-2 infection by vaccinating patients with acute leukemia receiving antitumor treatment. If the immunological response to vaccination is insufficient, it is possible to use virus-neutralizing monoclonal antibodies as a safe and effective method of primary prevention of COVID-19.

show abstract

“…Since then, multiple questions have arisen related to the prognosis and care of cancer patients. Initially, recommendations formulated by groups of experts were issued in order to guide the care of patients with hematological neoplasms and COVID19; subsequently, the experience of various regions of the planet was published, with variable mortality rates [1][2][3][4].…”

Section: Introductionmentioning

confidence: 99%

Survival of Patients with Hematologic Malignancies and Covid-19

Gilberto¹

2022

J Hematol Thromb

View full text Add to dashboard Cite

The present study aimed to describe the characteristics of patients with hematological neoplasms and COVID19, treated in a reference center in Mexico City, as well as their mortality and the factors that could influence it.Patients and methods: This retrospective study included 56 patients with hematological neoplasms and SARS-CoV-2 infection. The impact on overall survival (OS) of sex, age, malignancy status, diabetes mellitus, obesity, overweight, neutrophil count, lymphocyte count, CO-RADS was evaluated.Results: Overall mortality was 50%. Univariate analysis identified age >50 years, history of hypertension, diabetes, and a CO-RADS score >5 as factors influencing the mortality of patients with hematologic malignancies and COVID19. Multivariate analysis only identified CO-RADS score > 5. Conclusion:The mortality of patients with hematological neoplasms and COVID19 was high in our setting. Frequent co morbidities in our population can influence mortality.

show abstract

The impact of lockdown during the COVID-19 pandemic on newly acute myeloid leukemia patients: Single-centre comparative study between 2019 and 2020 cohorts in Madrid

Cited by 6 publications

References 13 publications

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic

COVID-19 in patients with acute leukemia: 3 years' experience of pandemic

Survival of Patients with Hematologic Malignancies and Covid-19

Contact Info

Product

Resources

About